Completed PHASE4 INTERVENTIONAL 4-arm NCT02458417

Autologous Cell Suspension Grafting Using ReCell in Vitiligo and Piebaldism Patients

Autologous Cell Suspension Grafting Using ReCell in Vitiligo and Piebaldism Patients: a Randomized Controlled Study on the Recipient Site Preparation

Sponsor: Avita Medical

Conditions Piebaldism Segmental Vitiligo

Interventions Fractional CO2 laser 7.5 mJ, 20% Full surface CO2 laser 150 mJ Full surface CO2 laser 200 mJ ReCell

Updated 6 times since 2017 Last updated: Mar 31, 2017 Started: May 31, 2015 Primary completion: Jan 31, 2016 Completion: Jan 31, 2016

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE4 clinical study on Piebaldism and Segmental Vitiligo, this trial is completed. The trial is conducted by Avita Medical and has accumulated 6 data snapshots since 2015. Psychiatric clinical trials are essential for establishing evidence-based treatment standards.

Status Flow

Change History

6 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE4
Jul 2024 — Sep 2024 [monthly]

Completed PHASE4
Jan 2021 — Jul 2024 [monthly]

Completed PHASE4
Jun 2018 — Jan 2021 [monthly]

Completed PHASE4
May 2017 — Jun 2018 [monthly]

Completed PHASE4

Status: Enrolling By Invitation → Completed

▶ Show 1 earlier version

Jan 2017 — May 2017 [monthly]

Enrolling By Invitation PHASE4

First recorded

May 2015

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Avita Medical
Netherlands Institute for Pigment Disorders

Data source: Netherlands Institute for Pigment Disorders

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Amsterdam, Netherlands